Key facts
- It has raised $600K; the latest was Grant ($30K) in Feb 2026.
- Notable investors include Innovate UK, Creative Destruction Lab, University of Toronto, Development Bank of Wales, Welsh Government — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for MeOmics
- ·The full record, as it builds
Funding rounds
No funding rounds for MeOmics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MeOmics
Developer of therapies designed for the treatment of mental health conditions. The company's platform uses physiological assays to measure biological readouts from interacting neurons derived from clinically and genetically characterised patient stem cell lines, enabling clinicians and researchers in mental healthcare to support personalised treatment decisions and improve care outcomes.
- Sector
- Healthcare
- HQ
- Cardiff, United Kingdom
- Founded
- 2020
- Employees
- 8
- Website
- meomics.tech/
- Ownership
- Privately Held (backing)
MeOmics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MeOmics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MeOmics in its N-PORT filings yet. We sweep new filings monthly.